MAXIPIME

Compare MAXIPIME  to:
Compare
Compare

Generic Name for MAXIPIME

Cefepime (as HCl) 500mg, 1g, 2g; pwd for IV infusion or IM inj after reconstitution.

Legal Classification:

Rx

Pharmacological Class for MAXIPIME

Cephalosporin.

Manufacturer of MAXIPIME

Elan Pharmaceuticals

Indications for MAXIPIME

Susceptible infections, including moderate-to-severe pneumonia, uncomplicated skin and skin structure infections, complicated and uncomplicated urinary tract infections (UTIs) including pyelonephritis, complicated intraabdominal in adults (w. metronidazole). Empiric therapy in febrile neutropenia.

Adult dose for MAXIPIME

When giving IV, infuse over 30 minutes. Pneumonia: 1–2g IV every 12 hrs for 10 days. Skin and skin structures, severe UTIs: 2g IV every 12 hrs for 10 days. Mild-to-moderate UTIs: 500mg–1g IV or IM every 12 hrs for 7–10 days (IM only for UTIs caused by E. coli). Intraabdominal (use w. metronidazole): 2g IV every 12 hrs for 7–10 days. Febrile neutropenia: 2g IV every 8 hrs for 7 days or until neutropenia resolves. CrCl ≤60mL/min: reduce dose; see literature. Hemodialysis: repeat initial dose after each session. Continuous ambulatory peritoneal dialysis: give usual doses at 48-hour intervals.

Children's dosing for MAXIPIME

<2months: not recommended. Not for use in serious infection when pathogen is or may be H. influenzae type b. 2months–16yrs (≤40kg): 50mg/kg per dose, given every 12 hrs; do not exceed recommended adult dose. Severe UTIs, pneumonia, skin and skin structure: give IV for 10 days. Mild-to-moderate UTIs: give IV or IM for 7–10 days (IM only for UTIs caused by E. coli). Febrile neutropenia: give IV every 8 hours for 7 days or until neutropenia resolves.

Contraindications for MAXIPIME

Penicillin or other β-lactam allergy.

Warnings/Precautions for MAXIPIME

Renal impairment. Renal or hepatic dysfunction, poor nutritional state, prolonged antimicrobial therapy: monitor prothrombin time. History of GI disease (esp. colitis). Labor & delivery. Pregnancy (Cat.B). Nursing mothers.

Interactions for MAXIPIME

Aminoglycosides may potentiate oto- or nephrotoxicity. Possible nephrotoxicity with diuretics (eg, furosemide). May cause false (+) Coomb's, Clinitest.

Adverse Reactions for MAXIPIME

Local reactions (eg, pain, phlebitis, inflammation), rash, GI disturbances, pruritus, fever, headache, seizures, encephalopathy, blood dyscrasias, anemia, renal dysfunction, others.

How is MAXIPIME supplied?

Vials (500mg, 1g, 2g)—10

Related Disease:

Infections, bacterial~systemic antiinfectives
Pneumonia

Related Resources

Tygacil labeling updated to include increased mortality risk

September 01, 2010

The FDA is reminding healthcare professionals that intravenous Tygacil (tigecycline, from Pfizer) can increase mortality risk in the treatment of serious bacterial infections.

Phase 3 study of torezolid for acute bacterial skin and skin structure infections

August 30, 2010

Trius Therapeutics announced the initiation of its Phase 3 study of oral torezolid phosphate for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

FDA warns of eosinophilic pneumonia risk with Cubicin

July 29, 2010

The FDA has notified healthcare professionals and patients about the potential for developing eosinophilic pneumonia while receiving the antibiotic Cubicin (daptomycin, from Cubist).

FDA warns of counterfeit Tamiflu product

June 18, 2010

The FDA has warned consumers about a potentially harmful product represented as "Generic Tamiflu" sold over the Internet.

Claris Lifesciences' intravenous medications recalled

June 01, 2010

The FDA has notified healthcare professionals not to use the intravenous medications, metronidazole, ciprofloxacin and ondansetron manufactured by Claris Lifesciences due to contamination.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions